ClinicalTrials.gg
CompletedNCT02848261Updated Nov 12, 2019

Remote Monitoring of Diabetes in Young Children With Type 1 Diabetes

An interventional study of Developmental Demands and Distress Reduction in Type 1 Diabetes Mellitus, sponsored by Stanford University. Completed at 4 sites in United States. Open to participants aged 2 Years to 6 Years. Per ClinicalTrials.gov, last updated 2019-11-12.

Sponsored by Stanford University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
2 Years to 6 Years
Sex
All
01

Study summary

The primary objective of this project is to examine the impact of a continuous glucose monitoring (CGM) intervention on health and psychological outcomes in young children with type 1 diabetes (T1D).

02

Conditions studied

  • Type 1 Diabetes Mellitus
03

In context

Diabetes Mellitus, Type 1

3,614 studies on the registry are indexed under Diabetes Mellitus, Type 1; 586 are open to participants now.

This study's enrollment of 92 is above the median of 40 across 2,718 interventional studies indexed under Diabetes Mellitus, Type 1.

Browse Diabetes Mellitus, Type 1 studies →

Lead sponsor

Stanford University is the lead sponsor of 2,161 studies on the registry; 428 are open to participants now.

Of its 268 completed or terminated interventional studies of FDA-regulated products, 207 (77%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 6 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

To be eligible for the study, a child must meet the following criteria:

  1. Diagnosis of type 1 diabetes according to American Diabetes Association diagnostic criteria
  2. Time since diagnosis of at least six months
  3. Age between 2 and 6 years at enrollment
  4. Parental consent to participate in the study
  5. No severe medical conditions, which in the opinion of the investigators are likely to hinder participation in this clinical trial.
  6. If current use of CGM, A1c has to be above 7.5%; value obtained within 3 months of enrollment
  7. Own and use an iPhone, or be willing/able to carry a study-supplied wi-fi enabled iPod

To be eligible for the study, a parent must meet the following criteria:

  1. Parent or legal guardian of a child with type 1 diabetes meeting the "child" criteria outlined above
  2. Age of 18.0 years or older
  3. Parent comprehends written English
  4. Parent understands the study protocol and signs the informed consent document
  5. Parent has access to a personal computer to upload diabetes devices and send to research team

The presence of any of the following is an exclusion for the study:

  1. Child has a medical disorder that in the judgment of the investigator will interfere with completion of any aspect of the protocol (e.g., pregnancy, kidney disease, adrenal insufficiency, skin condition that may hinder sensor application).
  2. Child has a neurologic disorder that in the judgment of the investigator will affect completion of the protocol
  3. Current use of oral glucocorticoids or other medications, which in the judgment of the investigator would be a contraindication to participation in the study
  4. Child is unable to completely avoid acetaminophen for duration of study
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
92 participants (actual)

Study arms

  • Experimental
    Developmental Demands

    Provide education on using diabetes technology in various settings and formats in this age group, and increase ability for real-time problem-solving.

    Behavioral: Developmental Demands

  • Experimental
    Distress Reduction

    Identify and reduce parent distress symptoms and worries. Provide strategies for obtaining social support.

    Behavioral: Distress Reduction

  • Experimental
    Remote Monitoring

    Optimize the use of remote monitoring by focusing on situational demands and problem solving.

    Behavioral: Remote Monitoring

  • Experimental
    Fear of Hypoglycemia

    Decrease fear of hypoglycemia, particularly focusing on overnight glycemic control.

    Behavioral: Fear of Hypoglycemia

  • Placebo comparator
    No Intervention

    Serves as the control group comparator. No intervention provided.

    Behavioral: No intervention

Interventions

  • BehavioralDevelopmental Demands

    Education and training related to use of CGM in this age group

  • BehavioralDistress Reduction

    Education and training on reducing distress

  • BehavioralRemote Monitoring

    Education and training on the use of remote monitoring

  • BehavioralFear of Hypoglycemia

    Education and training on reducing fear of hypoglycemia

  • BehavioralNo intervention

    No intervention - serves as the control group

06

What researchers measure

Primary outcomes

  1. Time spent in blood glucose range

    Increasingly it is recognized that the percent time spent in a target blood glucose range, which is set by the American Diabetes Association, is an important outcome. This measure will be used as a primary outcome and derived from objective data downloads.

    Time frame: Change over 6 months

  2. Pediatric Quality of Life Inventory

    This is a measure of health-related quality of life. It is used to understand the broader impact on quality of life which includes social, psychological, and health aspects of daily living.

    Time frame: Change over 6 months

Secondary outcomes

  1. A1c

    The hemoglobin A1c value is a biologic measure of the glycemia that is the gold standard measure of "control" of diabetes. Collected through a blood sample.

    Time frame: Change over 6 months

  2. Problem Areas in Diabetes

    This measure captures areas that are reported as problems for people with diabetes. Participants in the study report on daily problems with diabetes via this measure.

    Time frame: Change over 6 months

  3. Diabetes Distress Scale

    This measure is widely used to capture the psychological distress experienced in relation to diabetes.

    Time frame: Change over 6 months

  4. Patient Health Questionnaire 9

    This is a widely used measure that captures depressive symptoms. It is reported by the participants.

    Time frame: Change over 6 months

  5. State-Trait Anxiety Inventory

    This is a widely used measure of anxiety symptoms. It is reported by the participant.

    Time frame: Change over 6 months

  6. Pittsburgh Sleep Quality Index

    This questionnaire measures the degree to which sleep is disrupted and the quality of sleep experienced by participants.

    Time frame: Change over 6 months

  7. Hypoglycemic Fear Survey

    People with diabetes worry about hypoglycemia. This measure captures those worries and is reported by participants.

    Time frame: Change over 6 months

  8. Hypoglycemic Confidence Questionnaire

    Hypoglycemia needs to be managed in various daily situations. This questionnaire captures confidence of the participants in those various situations.

    Time frame: Change over 6 months

  9. Glucose Monitoring System Satisfaction Survey

    This a measure used to capture overall satisfaction with glucose monitoring devices used by participants.

    Time frame: Change over 6 months

  10. General and diabetes-specific technology use

    This measure has questions on attitudes and use of various general technologies (e.g., smartphone) and diabetes devices.

    Time frame: Change over 6 months

07

Study locations

4 sites
  • Stanford University
    Stanford, California 94305, United States
  • University of Colorado
    Aurora, Colorado 80045, United States
  • University of South Florida
    Tampa, Florida 33620, United States
  • Indiana University
    Indianapolis, Indiana 46202, United States
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 12, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02848261
Responsible party
Korey Hood (Professor, Stanford University) — Principal investigator
First posted
Jul 28, 2016
Start date
Aug 15, 2016
Primary completion
Apr 2019
Completion
Apr 2019
Last update
Nov 12, 2019

Study contacts

Bruce Buckingham, MD
principal investigator · Stanford University
Kimberly Driscoll, PhD
principal investigator · University of Colorado, Denver
Linda DiMeglio, MD
principal investigator · Indiana University
Henry Rodriguez, MD
principal investigator · University of South Florida

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion